...
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial.
【24h】

Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial.

机译:用多奈哌齐作为标准医疗的辅助疗法,增强急性缺血性中风后的恢复:IIA期临床试验的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Our aim was to assess the safety, tolerability, and efficacy signal of early donepezil administration with regard to enhancing recovery in a diverse acute ischemic stroke population. METHODS: This was a multicenter, single-arm, National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator trial-controlled, modified 2-stage adaptive clinical trial set in 2 tertiary care hospitals in the United States. Adults with ischemic stroke treated within 24 hours after onset of symptoms were included. The intervention studied was donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days. Our main outcome measures included treatment-related adverse events and side effects. The primary favorable outcome was a 90-day National Institutes of Health Stroke Scale (NIHSS) score
机译:背景:我们的目的是评估早期多奈哌齐给药在增强各种急性缺血性卒中人群的恢复方面的安全性,耐受性和疗效信号。方法:这是在美国2家三级护理医院进行的多中心,单臂,国家神经病学和中风重组组织纤溶酶原激活物试验控制,改良的2阶段适应性临床试验。包括症状发作后24小时内接受治疗的缺血性中风成人。研究的干预措施是多奈哌齐5毫克/天,持续30天,然后增加至10毫克/天,持续60天。我们的主要结局指标包括与治疗相关的不良事件和副作用。主要的有利结果是90天的美国国立卫生研究院卒中量表(NIHSS)得分

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号